MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tauopathies"

  • 2024 International Congress

    Dermal 4R-Tau seeding as a novel biomarker for Progressive Supranuclear Palsy

    I. Martinez-Valbuena, D. Olszewska, M. Sousa, T. Abkur, N. Bendahan, N. Reyes, M. Emamikhah Abarghouei, C. Ghadery, L. Armengou Garcia, J. Liao, C. Tan, SM. Fereshtehnejad, H. Alotibi, JC. Vargas-Gonzalez, NC. Dimal, J. Li, P. Bhakta, R. Cheung, J. Sasitharan, N. Visanji, S. Fox, C. Tartaglia, A. Lang, G. Kovacs (Toronto, Canada)

    Objective: To ascertain the presence of misfolded tau species in the skin of Progressive Supranuclear Palsy (PSP) patients and evaluate its utility as a potential…
  • 2024 International Congress

    Is cathepsin D a good target for therapy in Tau-related conditions?

    G. Kovacs, A. Jafrani, G. Puska, I. Martinez-Valbuena, S. Lee, S. Knott, A. Karakani, S. Tanikawa, A. Lang, S. Forrest (Toronto, Canada)

    Objective: To study the involvement of cathepsin D in the pathogenesis of Tau-related conditions. Background: The endo-lysosomal system (ELS) is central in processing of neurodegenerative…
  • 2024 International Congress

    Tau Deposition in Locus Coeruleus is Associated with Rapid Eye Movement Sleep Behavior Disorder in Progressive Supranuclear Palsy.

    X. Li, FT. Liu (Shanghai, China)

    Objective: In this study, we aimed to investigate the frequency of Rapid eye movement sleep behavior disorder (RBD) occurring in a large cohort of PSP,…
  • 2024 International Congress

    Longitudinal progress and clinical relevance of 18F-Florzolutau PET in patients with PSP: a one-year follow-up study

    J. Wang, F. Liu, C. Zuo (Shanghai, China)

    Objective: Here we aimed to explore the progress of 18F-Florzolotau PET and its clinical relevance in patients with PSP during one-year follow-up. Background: The 18F-Florzolotau…
  • 2023 International Congress

    Introducing the molecular subtyping of Progressive Supranuclear Palsy: a proof of concept

    I. Martinez-Valbuena, S. Lee, E. Santamaria, J. Fernandez-Irigoyen, B. Couto, N. Reyes, H. Tanaka, S. Forrest, A. Kim, H. Qamar, J. Li, A. Karakani, K. Senkevich, E. Rogaeva, N. Visanji, A. Lang, G. Kovacs (Toronto, Canada)

    Objective: To enhance understanding of the molecular mechanisms underlying disease heterogeneity in Progressive supranuclear palsy (PSP) Background: PSP is a 4R-tauopathy characterised by subcortical pathology…
  • 2023 International Congress

    Transferrin as a possible CSF biomarker in neurodegenerative proteinopathies

    K. Mensikova, P. Kanovsky, K. Klicova, D. Konickova, S. Kurcova, M. Nevrly, P. Otruba, Z. Grambalova, M. Kaiserova, J. Zapletalova (Olomouc, Czech Republic)

    Objective: The aim of this study was to determine whether cerebrospinal fluid (CSF) levels of transferrin differ between patients with Parkinson´s disease (PD), multiple system…
  • 2023 International Congress

    Phenotypic characterization of 104 patients with Progressive Supranuclear Palsy: A Tertiary care experience from South India

    R. Yadav, S. Dey, N. Kamble, V. Holla, R. Mahale, M. Debnath, P. Pal (Bangalore, India)

    Objective: To prospectively evaluate and subtype the patients of Progressive supranuclear palsy being referred to a tertiary care movement disorders facility in South India. Background:…
  • 2023 International Congress

    Early-onset cortico-basal degeneration (CBD) due to a c.2092G>A MAPT mutation

    M. Mata Alvarez-Santullano, L. Lopez-Manzanares, J. Lopez-Lozano, N. Villares, C. Magdaleno, C. Dela Torre (Madrid, Spain)

    Objective: To describe a patient with early-onset atypical parkinsonism that evolved to a classic CBD without dementia, associated to a c.2092G>A MAPT mutation Background: Although…
  • 2023 International Congress

    Cell-specific MAPT gene expression is preserved in tau cytopathologies in Progressive Supranuclear Palsy

    S. Forrest, S. Lee, N. Nassir, V. Sackmann, I. Martinez-Valbuena1, J. Li, A. Ahmed, L. Ittner, A. Lang, M. Uddin, G. Kovacs (Toronto, Canada)

    Objective: To systematically map and quantify MAPT expression in neurons, astrocytes and oligodendroglia across different brain regions to determine whether cell type and/or regional differences…
  • 2023 International Congress

    Structural analysis of the basal ganglia using ex vivo 7T MRI can differentiate frontotemporal lobar degeneration with TDP-43 vs tau accumulation.

    R. Williamson, P. Khandelwal, S. Das, G. Mizsei, K. Prabhakaran, R. Ittyerah, D. Wolk, J. Detre, P. Yushkevich, E. Lee, J. Gee, M. Grossman, C. Mcmillan, M. Tisdall, D. Irwin (Philadelphia, USA)

    Objective: Ex vivo 7T MRI can identify macrostructural changes in the basal ganglia that reflect underlying neuropathology, and can be used to differentiate between proteinopathies…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 14
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley